Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 4/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.33 |
| ▸ | PDE4A | P27815 | 3/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12822514 | 0.91 | FPR2 (0.33) | FPR2PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL14765685 | 0.87 | FPR2 (0.36) | FPR2SCN9APDE4DPDE4APDE4B | |
| SCHEMBL12733925 | 0.86 | FPR2 (0.36) | FPR2SCN9APDE4DPDE4APDE4B | |
| SCHEMBL14765837 | 0.85 | FPR2 (0.39) | FPR2SCN9APDE4DPDE4APDE4B | |
| SCHEMBL12733928 | 0.83 | FPR2 (0.38) | FPR2SCN9APDE4DPDE4APDE4B | |
| SCHEMBL12733929 | 0.82 | FPR2 (0.37) | FPR2SCN9APDE4DPDE4APDE4B | |
| SCHEMBL12716349 | 0.82 | KDM1A (0.41) | FPR2APPKDM1AFAAH | |
| SCHEMBL12733930 | 0.82 | FPR2 (0.37) | FPR2SCN9APDE4DPDE4APDE4B | |
| SCHEMBL12717399 | 0.82 | KDM1A (0.38) | FPR2PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL12716621 | 0.82 | SCN9A (0.37) | FPR2SCN9APDE4DPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| WO-2009150966-A1 | TETRACYCLIC LIQUID CRYSTALLINE COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | チッソ株式会社 (JP) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | FPR2 589/4885SCN9A 2503/4885PDE4D 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.